資料下載
Data download
熱門(mén)搜索：
Fitzgerald Industries International代理
Envirologix 轉(zhuǎn)基因快速檢測(cè)試紙
Epitomics現(xiàn)貨抗體目錄
ABgene代理30
EVE™ Slide（EVE細(xì)胞計(jì)數(shù)板）
Cayman Chemical 特約代理
法國(guó)ID-VET
美國(guó)Sutter 玻璃毛坯 BF100-50-10
Sinobio公司產(chǎn)品介紹
polysciences公司中國(guó)總代理
Abcam代理
genview
D12079BWestern Diet(高純度飼料)
TEAA Solution（貨號(hào)：553303;SP5890）
LSPN-50ABMI公司LYSOSTAPHIN中國(guó)總代理
天然小鼠補(bǔ)體C1q蛋白
發(fā)布時(shí)間：2024/3/4
點(diǎn)擊次數(shù)：496
matriksbiotek2024年價(jià)格表
Matriks Biotek專(zhuān)門(mén)生產(chǎn)針對(duì)抗體藥的ELISA試劑盒，用于檢測(cè)抗體藥的體內(nèi)含量或因用于產(chǎn)生的針對(duì)相應(yīng)抗體藥的抗體的體內(nèi)含量。Matriks Biotek®, SHIKARI®和KLONART®為Matriks生物技術(shù)公司注冊(cè)的產(chǎn)品商標(biāo)。其產(chǎn)品達(dá)到ISO 13485 & CE IVD標(biāo)準(zhǔn)。
MatriksBiote抗體藥是一類(lèi)相對(duì)新型的生物制劑。檢測(cè)抗體藥及其抗體水平在治療和個(gè)性化用藥上具有重要意義。大量的臨床和制藥公司都在致力于抗體藥物的濃度水平和療效的研究。
特別告知：為保證產(chǎn)品質(zhì)量與良好性能，所以在購(gòu)買(mǎi)相應(yīng)產(chǎn)品的同時(shí)我司會(huì)收取一定量的運(yùn)輸費(fèi)用！！！本次報(bào)價(jià)有效時(shí)間為2024年1月8日---2024年12月14日。
| 貨號(hào) | 品名 | 規(guī)格 | 價(jià)格 | 品牌 | 貨期 | 價(jià)格來(lái)源 |
| ABA-FD-ORE | Abatacept (Orencia®) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ABA-QLS-ORE | Abatacept (Orencia®) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ABA-QNS-ORE | Abatacept (Orencia®) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-FD-HUM | Adalimumab (Humira®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-QLS-HUM | Adalimumab (Humira®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-QNFT-HUM | Adalimumab (Humira®) Antibody screening - Free/Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-QNS-HUM | Adalimumab (Humira®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ADA-SPEC-ADA | Adalimumab (Humira®) Free drug / Specific | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-FD-EYL | Aflibercept (Eylea®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-FD-SENS-EYL | Aflibercept (Eylea®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-QLS-EYL | Aflibercept (Eylea®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| AFL-QNS-EYL | Aflibercept (Eylea®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ATE-FD-TEC | Atezolizumab (Tecentriq®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ATE-QLS-TEC | Atezolizumab (Tecentriq®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| BEV-FD-AA | Bevacizumab (Avastin®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| CAN-FD-ILA | Canakinumab (Ilaris®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| CAN-QLS-ILA | Canakinumab (Ilaris®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| CAN-QNS-ILA | Canakinumab (Ilaris®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DAR-FD-DAR | Daratumumab (Darzalex®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DAR-QLS-DAR | Daratumumab (Darzalex®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DEN-QNS-PRO | Denosumab (Prolia®) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DUR-FD-IMF | Durvalumab (Imfinzi®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| DUR-QLS-IMF | Durvalumab (Imfinzi®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| ETA-FD-ENB | Etanercept (Enbrel®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| EVO-FD-REP | Evolocumab (Repatha® ) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| EVO-QLS-REP | Evolocumab (Repatha® ) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-FD-REMI | Infliximab (Remicade®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-FD-REMS | Infliximab (Remsima®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QLS-REMI | Infliximab (Remicade®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QLS-REMS | Infliximab (Remsima®) Antibody screening - Qualitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNFT-REMI | Infliximab (Remicade®) Antibody screening - Free/Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNFT-REMS | Infliximab (Remsima®) Antibody screening - Total semiquantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNS-REMI | Infliximab (Remicade®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-QNS-REMS | Infliximab (Remsima®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| INF-SPEC-INF | Infliximab (Remicade®) Free drug / Specific | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| NIV-FD-OPD | Nivolumab (Opdivo®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PAL-FD-SYN | Palivizumab (Synagis® ) Free drug | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PAL-QLS-SYN | Palivizumab (Synagis® ) Antibody screening - Qualitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PAL-QNS-SYN | Palivizumab (Synagis® ) Antibody screening - Quantitative | 96T | 13541.38 | matriksbiotek | 3-4周 | 上海起發(fā) |
| PEM-FD-KEY | Pembrolizumab (Keytruda®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RAN-FD-LUC | Ranibizumab (Lucentis®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RIT-FD-RM | Rituximab (Rituxan®, Mabthera®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RIT-QLS-RM | Rituximab (Rituxan®, Mabthera®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| RIT-QNS-RM | Rituximab (Rituxan®, Mabthera®) Antibody screening - Quantitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| SEC-FD-VER | Secukinumab (Cosentyx® , Verxant®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| SEC-QLS-VER | Secukinumab (Cosentyx® , Verxant®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| TOC-QNS-ACT | Tocilizumab (Actemra®) Antibody screening - Quantitative | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| TRA-FD-HH | Trastuzumab (Herceptin®, Herclon®) Free drug | 96T | 11834.48 | matriksbiotek | 3-4周 | 上海起發(fā) |
| UST-QLS-STE | Ustekinumab (Stelara®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| VED-FD-ENT | Vedolizumab (Entyvio®) Free drug | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
| VED-QLS-ENT | Vedolizumab (Entyvio®) Antibody screening - Qualitative | 96T | 12289.66 | matriksbiotek | 3-4周 | 上海起發(fā) |
（*此為部分產(chǎn)品價(jià)格完整價(jià)格請(qǐng)下載文件）
關(guān)鍵詞：matriksbiotek、Matriks Biotek®、KLONART®、SHIKARI®、ELISA試劑盒
文件下載
當(dāng)前位置：
